CPT|CAS 35873-49-5|DC Chemicals

Cas No.:	35873-49-5
Chemical Name:	8-Cyclopentyl-1,3-dimethylxanthine
Synonyms:	1H-Purine-2,6-dione,8-cyclopentyl-3,9-dihydro-1,3-dimethyl-;8-Cyclopentyl-1,3-dimethylxanthine;8-cyclopentyl-1,3-dimethyl-7H-purine-2,6-dione;8-CYCLOPENTYL-1,3-DIMETHYLXANTHINE,WHITE TO OFF-WHITE SOLID;1,3-dimethyl-8-cyclopentylxanthine;8-Cyclopentyl theophylline;8-cyclopentyl-1,3-dimethyl-3,7-dihydro-purine-2,6-dione;8-Cyclopentyltheophylline CPT;cyclopentyl teophylline;Theophylline,8-cyclopentyl;Xanthine,8-cyclopentyl-1,3-dimethyl;CPT;8-Cyclopentyltheophylline;Lopac0_000391;NCGC00015178-05;HMS2231K17;NSC 101806;SR-01000075232-1;E72267;NCGC00261076-01;LP00391;MFCD00055116;8-Cyclopentyl-1,3-dimethylxanthine, >=98% (HPLC), powder;PDSP1_000994;HMS502J06;NCIOpen2_006919;BRD-K38347298-001-06-4;GTPL385;Spectrum5_001769;Tox21_500391;L000085;AKOS027320620;NCGC00015178-06;NCGC00093819-03;SMR000326793;8-Cyclopentyl-1,3-dimethyl-1H-purine-2,6(3H,7H)-dione;CCG-221695;DTXSID70189432;Mol Pharmacol 29: 331 (1986);HY-W011955;SCHEMBL18029489;UNII-U7PWT4CPL5;KBio2_000831;1H-Purine-2, 8-cyclopentyl-3,7-dihydro-1,3-dimethyl-;PDSP2_000978;SCVHFRLUNIOSGI-UHFFFAOYSA-N;Spectrum2_001734;EU-0100391;NSC_1917;35873-49-5;NCGC00093819-02;1H-Purine-2,6-dione, 8-cyclopentyl-3,9-dihydro-1,3-dimethyl-;BRD-K38347298-001-02-3;NCGC00015178-07;BSPBio_002295;CAS_1917;8-Cyclopentyl-1,3-dimethylxanthine?;CHEMBL106265;8-cyclopentyl-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione;SCHEMBL431907;NCGC00015178-04;IDI1_000824;BDBM81925;NCGC00015178-02;8-CYCLOPENTYL-3,9-DIHYDRO-1,3-DIMETHYL-1H-PURINE-2,6-DIONE;NSC101806;8-cyclopentyltheophylline (cpt);NCGC00093819-04;EN300-223002;KBio3_001515;Z3247223614;CCG-39502;NCGC00015178-10;CHEBI:109538;8-Cyclopentyl-1,3-dimethyl-3,7-dihydro-purine-2,6-dione;DivK1c_000824;Spectrum4_000760;CS-W012671;Lopac-C-102;Q4644273;Theophylline, 8-cyclopentyl-;NCGC00093819-01;8-cyclopentyltheophylline;BRN 1133199;SDCCGSBI-0050378.P003;SR-01000075232;KBio1_000824;KBioSS_000831;HMS3261O03;Spectrum3_000658;AKOS030211020;NSC-101806;NINDS_000824;NCGC00015178-01;FT-0639285;KBio2_003399;SPBio_001808;NCGC00015178-03;Xanthine, 8-cyclopentyl-1,3-dimethyl-;Spectrum_000351;1H-Purine-2,6-dione, 8-cyclopentyl-3,7-dihydro-1,3-dimethyl-;U7PWT4CPL5;PD-116600;CPT; 8-Cyclopentyltheophylline;HMS3374O03;MLS000859932;KBioGR_001120;KBio2_005967;SPECTRUM2300193
SMILES:	CN1C2=C(C(=O)N(C)C1=O)N=C(C3CCCC3)N2
Formula:	C₁₂H₁₆N₄O₂
M.Wt:	248.28104
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.